New combo aims to fix Chemo's lingering side effect in cancer survivors
NCT ID NCT07586813
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding all-trans retinoic acid to romiplostim N01 can better raise platelet counts in adults who have low platelets after finishing chemotherapy for gastrointestinal cancers. About 220 participants will receive either the combo or romiplostim alone for 12 weeks. The main goal is to see if more people achieve a safe platelet level with the combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Romiplostim N01 (a platelet-boosting drug) and all-trans retinoic acid (a vitamin A derivative)
- What this could lead to
- If it works, this combination could offer a new way to safely raise platelet counts in cancer survivors, reducing bleeding risk and the need for platelet transfusions.
- What could go wrong
- This is a mid-stage trial with only 220 people, so results may not apply to everyone. The drugs can cause side effects like bone pain or liver issues, and the combo might not work better than the single drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?